Absci is trading at $9.98, up 10.02%, with available news pointing to biotech-sector strength; no fresh company-specific catalyst was identified for October 21.
- XBI gained 2.10%; sector coverage also cited positive sentiment around Merck KGaA’s agreement to acquire Silence Therapeutics and positive clinical-trial news.
- The acquisition concerns a different biotech company and is sector context, not an Absci deal.
- Trading volume was not provided, so activity versus average cannot be assessed.